Back to results
US 2025/0059544 A1Published application
Antisense oligonucleotides (asos) that suppress sars-cov-2 replication
AssigneeChildren's Medical Center Corporation
InventorsHao Wu, Longfei Wang, Setu M. Vora
Life of this patent
Estimating the term…
Abstract
Provided herein are antisense oligonucleotides for use in targeting SARS-CoV-2. Also provided herein are compositions comprising such oligonucleotides and methods for administering the oligonucleotides or compositions thereof to a subject for the purpose of treating or preventing a SARS-CoV-2 infection.
Claims34
An oligonucleotide comprising a region of complementarity to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 5′ untranslated region (UTR) target sequence set forth in SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.